血液透析患者急性早幼粒细胞白血病的成功治疗。
Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis.
机构信息
Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya Takatsu, Kawasaki, Kanagawa, 213-8587, Japan.
出版信息
Clin Exp Nephrol. 2011 Jun;15(3):434-437. doi: 10.1007/s10157-011-0405-5. Epub 2011 Feb 5.
Acute promyelocytic leukemia (APL) has the best prognosis among acute leukemias, but there is little data about APL in patients on hemodialysis. A 64-year-old hemodialysis patient was successfully treated for APL by induction therapy with all-trans retinoic acid (ATRA), three courses of consolidation therapy with Ara-C, mitomycin C (MIT), daunorubicin (DNR), and idarubicin (IDR), and maintenance therapy with ATRA. Complete remission has been maintained for 42 months in this patient. With dose modification, ATRA and chemotherapy may be safely given to patients on hemodialysis.
急性早幼粒细胞白血病 (APL) 在急性白血病中预后最好，但关于血液透析患者的 APL 数据较少。我们成功地对一名 64 岁血液透析患者采用全反式维甲酸（ATRA）诱导治疗、3 个周期阿糖胞苷（Ara-C）、丝裂霉素 C（MIT）、柔红霉素（DNR）和伊达比星（IDR）巩固治疗以及 ATRA 维持治疗来治疗 APL。该患者的完全缓解已维持 42 个月。通过剂量调整，ATRA 和化疗可安全地用于血液透析患者。
Zotero 插件